1. Class III β-Tubulin Overexpression Is a Marker of Poor Clinical Outcome in Advanced Ovarian Cancer Patients
   Gabriella Ferrandina et al, 2006, Clinical Cancer Research CrossRef
2. Prediction of individual response to platinum/paclitaxel combination using novel marker genes in ovarian cancers
   Masaaki Komatsu et al, 2006, Molecular Cancer Therapeutics CrossRef